GlassScriptPhysician profile
Jacob H Edwards
NPI 1730323254
$2,673.05
in general payments reported to CMS, 2019-2025
40 companies · $151 in 2025
The $151 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.50 · 2020: $308 · 2021: $546 · 2022: $1,074 · 2023: $410 · 2024: $139 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $427.83 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $300.69 | 2020-2023 | Xywav |
| Novo Nordisk INC | $188.07 | 2020-2022 | |
| Tris Pharma INC | $180.25 | 2019-2023 | Dyanavel Xr, Quillichew Er, Quillivant |
| Corium, LLC | $176.65 | 2022-2025 | Azstarys |
| Eisai INC. | $152.43 | 2020-2022 | |
| Rhythm Pharmaceuticals, INC. | $118.50 | 2023-2024 | Imcivree, Imcivree |
| Ucb, INC. | $107.84 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $102.69 | 2020-2022 | |
| Ascendis Pharma Endocrinology INC | $72.53 | 2022 | |
| Genzyme Corporation | $66.07 | 2022-2023 | |
| Greenwich Biosciences, INC. | $58.59 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $57.63 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $46.59 | 2022 | |
| Tolmar, INC. | $45.02 | 2024-2025 | Fensolvi |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.